Shire sells eight 'non-core' products for $213 million

Share this article:

Shire said today that it is selling eight “non-core” products to Spanish company Almirall for $213 million.

“The divested products are no longer core to Shire's strategy of building market leading positions in specialty markets,” the company said in a statement.

Shire said its focus is moving forward will be on building its attention deficit hyperactivity disorder, human genetic therapies, gastrointestinal and renal diseases businesses and, with its recent in-licensing of Juvista (human recombinant), to build a new specialty area of regenerative medicine.

There are eight products being sold in the transaction. They include:

* Lodine (etodolac) for treatment of rheumatoid arthritis.

* Colazide (balsalazide) for treatment of mild to active ulcerative colitis.

* Meptid (meptazinol hydrochloride) for treatment of pain.

*Cebutid (flurbiprofen) for treatment of the symptoms of rheumatoid arthritis and osteoarthritis.

*Robaxin (methocarbamol) for relief of pain from muscle injuries, spasms, sprains and strains.

*Mintec (peppermint oil) for the relief of discomfort associated with irritable bowel syndrome.

*Solaraze (diclofenac sodium) is a topical preparation for the treatment of actinic keratoses.

*Vaniqa (eflornithine) is a topical prescription medicine for treating unwanted facial hair in women.
 
Almirall chairman and CEO Jorge Gallardo said in a statement the acquisition would expand his company's international presence and “reinforces our position as one of the key European specialty pharmaceutical companies.”

Share this article:
You must be a registered member of MMM to post a comment.

Email Newsletters

MM&M EBOOK: PATIENT ACCESS

Patient access to pharmaceuticals is a tale of two worlds—affordability has improved for the majority, while the minority is hampered by cost, distribution and red tape. To provide marketers with a well-rounded perspective, MM&M presents this e-book chock full of key insights. Click here to access it.

More in Channel

Five things for pharma marketers to know: Monday, September 15

Five things for pharma marketers to know: ...

Pharma has sought 76 meetings with FDA over biosimilars; Gilead licenses Sovaldi to India generic drugmakers; Pfizer and Ranbaxy Lipitor lawsuit dismissed.

Liraglutide, aiming for new indication, gets new name

Liraglutide, aiming for new indication, gets new name

Why Novo Nordisk is choosing not to leverage Victoza's brand equity as it seeks a weight-loss indication for liraglutide.

Five things for pharma marketers to know: Friday, September 12

Five things for pharma marketers to know: Friday, ...

An FDA panel voted in favor of liraglutide for weight loss; Allergan investors backing an attempted takeover of the firm crossed a critical threshold; and 100 million health wearables are ...